Sihuan Pharmaceutical (0460.HK) Obtained the Exclusive Distribution Right for LipiVage(R) Fat Collection System in Greater China and South Korea
HONG KONG, June 4, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that Meiyen Laboratory Inc, an Am...
Sihuan Pharmaceutical (0460.HK): 'A Friend of Time' 2021 - The Turning-point Year
HONG KONG, March 16, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. plays a pivotal role in China's domestic medical industry and is a leading company for the development of the country's cardio-cerebral vascular prescription drugs. According to IMS data in 2018, Sihuan Pharmaceut...
Sihuan Pharmaceutical (0460.HK): Be a friend of time, 2021 is the year of turning point
HONG KONG, March 10, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. plays a pivotal role in the domestic medical industry. It is a leading company inChina's CCV prescription drugs. According to IMS data in 2018, Sihuan Pharmaceutical is well-known on the national hospital prescrip...
Sihuan Pharmaceutical (0460.HK) The sole agent of Letybo 100U China AI Listing Conference was successfully held
HONG KONG, Feb. 5, 2021 /PRNewswire/ -- Exclusively represented by Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460), Letybo®100U, a type A botuli...
Sihuan Pharmaceutical (0460.HK): Xuanzhu Biopharm acquires Combio Pharmaceutical, the large-molecule integrated development platform helps drive innovation
HONG KONG, Jan. 27, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce its innovation Xuanzhu Biopharma...
Sihuan Pharmaceutical (0460) Won the Fifth "Listed Enterprises of the Year 2020" Presented by Bloomberg Businessweek/Chinese Edition
HONG KONG, Dec. 3, 2020 /PRNewswire/ -- Bloomberg Businessweek/Chinese Edition announced thatSihuan Pharmaceutical Holdings Group Ltd. (0460.HK) won the fifth "Listed Enterprises of the Year 2020". The event received enthusiastic support with enterprises from a wide range of industries participat...
Sihuan Pharmaceutical (0460.HK) receives approval for its exclusive medical aesthetic product Letybo (botulinum toxin), A blockbuster product in a hundred-billion size market
HONG KONG, Oct. 27, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460) is pleased announce that "Type A Botulinum Toxin for Injection" (Letybo 100U), a product exclusively distributed by Sihuan Pharmaceutical, has officially received the marketing approval from the Natio...
Sihuan Pharmaceutical's Gabapentin Capsules was Granted Drug Production Approval, the Third Company Obtained Approval in China
HONG KONG, Oct. 22, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd.(the "Company'' or ''Sihuan Pharmaceutical'', together with its subsidiaries, the ''Group''; HKEX stock code: 0460) is pleased to announce that the National Medical Products Administration has granted drug productio...
Sihuan Pharmaceutical Invests in Phase I Fund of Ascendum Capital Life Technology to Expand its Strategy in Development of Innovative Drugs
HONG KONG, Oct. 20, 2020 /PRNewswire/ -- On 20 October 2020, Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") announced that its participation in the investment of Phase I Fund of Ascendum Capital Life Te...
Sihuan Pharmaceutical (0460.HK): Under innovation transformation, an internationalized new pattern in construction
HONG KONG, Sept. 15, 2020 /PRNewswire/ -- Recently, share price of Sihuan Pharmaceutical (0460.HK) continued to rise, hittingHK$1.09 per share, up 53.52% from its low onMay 25. Judging from the stock price trend, the stock price of Sihuan Pharmaceutical seems to have entered the stage of reboundi...
SDIC leads the investment of Xuanzhu Biopharmaceutical with RMB 800 million, promoting innovation and R&D
HONG KONG, Aug. 24, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Xuanzhu Biopharmaceutical, its innovative drug research and development platform, su...
Sihuan Pharmaceutical Introduced Investors for Capital Increase to Accelerate Solid-liquid Double Chamber Infusion Soft Bag Industry
HONG KONG, Aug. 20, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Beijing Ruiye Drugs Manufacture Co., Ltd. ("Beijing Ruiye"), an associate of the Grou...
Drug Registration Approval Granted for Sihuan Pharmaceutical's Pediatric Compound Amino Acid Injection (18AA-II)
HONG KONG, March 23, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that drug registration approval has been granted by the National Medical Products Administ...
Sihuan Pharmaceutical Announces Clinical Research of Favipiravir, Co-Developed with the Academy of Military Medical Sciences of the People's Liberation Army, Has Commenced
HONG KONG, March 2, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the clinical research of Favipiravir tablet, which was co-developed by the Group and t...
Sihuan Pharmaceutical Announces Acquisition of All Interests and Intellectual Property Rights of Plazomicin, A New Generation of Aminoglycoside Antibiotics in the Greater China Region
HONG KONG, Feb. 20, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Xuanzhu (HK) Biopharmaceutical Limited (''Xuanzhu''), a wholly-owned subsidiary of the...
Sihuan Pharmaceutical: Production Approval Granted For Rivastigmine Hydrogen Tartrate Capsule, The First Drug Passing Consistency Evaluation And Levetiracetam Tablet And The First Registration Approval Granted For Midazolam Oromucosal Solution
HONG KONG, Feb. 18, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that rivastigmine hydrogen tartrate capsule and levetiracetam tablet developed by the Group...
Sihuan Pharmaceutical Accelerates Product Expansion in Digestive System and Liver Related Diseases
HONG KONG, Feb. 14, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd.(HKEX: 0460) ("Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the progress achieved by the Group in the research and development of drugs for treati...
Sihuan Pharmaceutical and Hetero Labs Limited Reached A Framework Cooperation Agreement in Pharmaceutical Manufacturing Area
HONG KONG, Feb. 12, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460) ("Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group and Hetero Labs Limited ("Hetero"), a company registered under the laws ofI...
Sihuan's Abstracts regarding Clinical Trial Progress of SGLT-2 Inhibitor Selected for Poster Presentation at the American Diabetes Association's Scientific Sessions
HONG KONG, June 10, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular drug manufacturer in China's prescription drug market, announced that three abstracts regarding the clinical trial of the Group's patented innovative drug Janaglif...
Sihuan Pharm Post-launching Large-scale Clinical Trials of Cinepazide Maleate Injection were Completed With Efficacy Verified
HONG KONG, June 1, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced that the Group has completed the post-launch clinical trials of "Cinepazide Maleate Inject...
